Latest University of Texas Health Science Center at San Antonio Stories
Azaya Therapeutics, Inc., announced today that it has signed a licensing agreement to further develop a breakthrough technology that uses liposomes to deliver radiation through direct injection into head and neck tumors, shrinking the tumor, delaying recurrence and avoiding the collateral tissue damage that often accompanies all other forms of radiation therapy.
CALGARY, June 20 /PRNewswire-FirstCall/ -- Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that following U.S. Food and Drug Administration (FDA) review, the Company is initiating a U.S.
Michael J. Wick, Ph.D., a recognized leader in the research of new anti-cancer drugs, has been named director of preclinical research at South Texas Accelerated Research Therapeutics (START). He will join the START team on Sept. 3. Dr.
Chris H. M. Takimoto, M.D., Ph.D., an internationally recognized leader in the development of new anti-cancer drugs, has been named director of pharmacology at South Texas Accelerated Research Therapeutics (START). Dr.
SAN ANTONIO, July 20 /PRNewswire/ -- The Cancer T
SAN ANTONIO, March 20 /PRNewswire-USNewswire/ -- San Antonio will be the epicenter of a national change in bicultural health care as Hispanic doctors from across the U.S. meet here March 23-25 to share innovative practices to treat diabetes, obesity, dementia and other diseases affecting Latinos.
- Growing in low tufty patches.